Abstract 712TiP
Background
CDK7, part of the CAK complex regulates cell cycle progression, making it a potential therapeutic target for malignancies with aberrant cell cycle regulation. Cell cycle arrest in cancer cells affects DNA damage repair and genomic instability, potentially triggering apoptosis and anti-tumor immune response. Q901, is a potent covalent CDK7 inhibitor, with demonstrated in vivo activity against resistant models, and has potential as a treatment for various cancers where standard care has failed.
Trial design
This phase 1/2 multicenter, open-label study (NCT05394103) evaluates the safety, pharmacodynamics, and pharmacokinetics of Q901 in adult patients with solid tumors in the USA and Korea. In phase 1 dose escalation, Q901 is administered intravenously once weekly for four weeks, then once every two weeks in patients with advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancers. The study will establish the MTD, DLT, and RP2D of Q901 monotherapy, using a modified Toxicity Probability Interval (mTPI) design targeting a DLT rate of ∼30%. Up to 6 dose levels/50 patients will be evaluated in phase 1. Upon determining the RP2D, the study advances to phase 2. Cohort 1 will recruit HR+ HER2- breast cancer patients receiving Q901 combined with fulvestrant, who have received at prior endocrine and CDK4/6 targeted treatment, along with up to two additional prior lines of systemic anticancer therapy. Cohort 2 consists of extensive-stage SCLC patients treated with Q901 monotherapy after failing first-line standard of care. Each cohort will enroll up to 20 patients to assess safety and activity in selected cancer types.
Clinical trial identification
NCT05394103.
Editorial acknowledgement
Legal entity responsible for the study
Qurient Co. Ltd.
Funding
Qurient Co. Ltd.
Disclosure
B. Choi, J. Ahn, J. Choi, K. Ahn, S. Ryu, J. Kim, D. Yu, S-J. Lee, B. Jeon, S. Proniuk, J. Kim, K. Nam: Financial Interests, Personal, Full or part-time Employment: Qurient Co. Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
668P - Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: Alexander Drilon
Session: Poster session 17
669P - Patient-reported outcomes with selpercatinib in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Presenter: Hyunseok Kang
Session: Poster session 17
670P - Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
Presenter: Panpan Zhang
Session: Poster session 17
671P - Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors
Presenter: Sanjay Goel
Session: Poster session 17
672P - Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Presenter: Rafal Dziadziuszko
Session: Poster session 17
673P - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
Presenter: Patrick Schoeffski
Session: Poster session 17
674P - Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia
Presenter: Raymond DeMatteo
Session: Poster session 17
675P - A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
Presenter: Jinming Yu
Session: Poster session 17
676P - Preclinical characterization of novel peptide binders for EphA2-targeted radiopharmaceutical therapy
Presenter: Renee Clift
Session: Poster session 17
677P - Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
Presenter: Yun Beom Sang
Session: Poster session 17